PUREPAC TO MERGE WITH FAULDING U.S. SUBSIDIARIES, CHANGE NAME to Faulding, Inc. in a series of transactions announced Aug. 10. Generic drug maker Purepac, which is 64%-owned by the Australian manufacturer Faulding, has agreed to acquire: Faulding Pharmaceuticals, which is Faulding's U.S. injectables marketing arm; Faulding Medical Devices, which is developing shell glass vial and device technologies; and Faulding Puerto Rico, which owns products and manufacturing facilities in Puerto Rico that formerly belonged to DuPont Merck.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.
The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.
